A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Tarimo, Edith A M ^a,b   Thorson, Anna ^a   Kohi, Thecla W ^b   Bakari, Muhammad ^b   Sandstrom, Eric ^a   Mhalu, Fred ^b   Kulane, Asli ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; CONSULTATION; CONTROLLED STUDY; COPING BEHAVIOR; FAMILY; FEMALE; FOLLOW UP; FRIEND; HEALTH CARE DELIVERY; HUMAN; HUMAN EXPERIMENT; INFORMATION PROCESSING; MALE; MEDICAL SERVICE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; QUALITATIVE ANALYSIS; RISK REDUCTION; SAFE SEX; SELF MEDICATION; SEX DIFFERENCE; SEXUAL BEHAVIOR; TANZANIA; VOLUNTEER; BEHAVIOR; CLINICAL TRIAL; EVALUATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ADULT; AIDS VACCINES; BEHAVIOR; EVALUATION STUDIES AS TOPIC; FEMALE; FOCUS GROUPS; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMAN EXPERIMENTATION; HUMANS; MALE; TANZANIA;

EID: 80054818178     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-283     Document Type: Article

References (32)

1. Milford C, Barsdorf N, Kafaar Z. What should South African HIV vaccine trials do about social harms?. AIDS Care 2007, 19(9):1110-1117. 10.1080/09540120701335212, 18058395.
2. Allen M, Israel H, Rybczyk K, Pugliese MA, Loughran K, Wagner L, Erb S. Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses 2001, 17(8):667-674. 10.1089/088922201750236942, 11429107.
3. Jenkins RA, Thapinta D, Morgan PA, Wongkamhaeng S, Sornsathapornkul P, Bussaratid V, Sontirat A, Pitisuttithum P, Thongchareoen P, Khamboonruang C, Suriyanon V, Nitayaphan S, Brown AE, . Thai AIDS Vaccine Evaluation Group Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr 2005, 40(5):592-599. 10.1097/01.qai.0000171725.09812.a5, 16284537, Thai AIDS Vaccine Evaluation Group.
4. Maek ANW, Pitisuttithum P, Phonrat B, Bussaratid V, Naksrisook S, Peonim W, Thantamnu N, Muanaum R. Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials. J Med Assoc Thai 2003, 86(4):299-307.
5. Fuchs J, Durham M, McLellan-Lemal E, Vittinghoff E, Colfax G, Gurwith M, Buchbinder S. Negative social impacts among volunteers in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2007, 46(3):362-368. 10.1097/QAI.0b013e3181565dcb, 17721399.
6. Pitisuttithum P, Choopanya K, Bussaratid V, Vanichseni S, van Griensven F, Phonrat B, Martin M, Vimutsunthorn E, Sangkum U, Kitayaporn D, Tappero JW, Francis D. Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. J Med Assoc Thai 2007, 90(11):2442-2448.
7. Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, Stablein D, Self S, McNamara J, Frey S, Flores J, Excler JL, Klein M, Habib RE, Duliege A, Harro C, Corey L, Keefer M, Mulligan M, Wright P, Celum C, Judson F, Mayer K, McKirman D, Marmor M, Woody G. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001, 183(9):1343-1352. 10.1086/319863, 11294665.
8. Database of AIDS Vaccine Candidate in Clinical Trials. (Accessed 2/1/2011)., http://www.iavireport.org/trials-db/Pages/default.aspx
9. Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris E, Lyamuya E, Janabi M, Mbwana J, Mwanyika L, Stout R, Hejdeman B, Brave A, Robb M, Marovich M, Michael N, Earl P, Moss B, Wahren B, Biberfeld G, Pallangyo K, Mhalu F, Sandstrom E. A low dose of multigene, multiclade HIV DNA given intrademally induces strong and broad immune responses after boosting with heterologous HIV MVA. Retrovirology 2009, 6(Suppl 3).
10. Thorne S. Interpretive Description 2008, CA: Left Cost Press Inc..
11. Tarimo EAM, Thorson A, Bakari M, Mwami J, Sandstrom E, Kulane A. Willingness to volunteer in a Phase I/II HIV vaccine trial: a study among police officers in Dar es Salaam, Tanzania. Global Health Action 2009, 2.
12. Tarimo EAM, Thorson A, Kohi TW, Mwami J, Bakari M, Sandstrom E, Kulane A. Balancing Collective Responsibility, Individual Opportunities and Risks: A Qualitative Study on how Police Officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania. BMC Public Health 2010, 10:292. 10.1186/1471-2458-10-292, 2888745, 20509908.
13. Tarimo EAM, Thorson A, Kohi TW, Bakari M, Mhalu F, Kulane A. Reasons for Declining to Enrol in a Phase I and II HIV Vaccine Trial after Randomization among Eligible Volunteers in Dar es Salaam, Tanzania. PLOS ONE 2011, 6(2):e14619. 10.1371/journal.pone.0014619, 3040178, 21358826.
14. International AIDS Vaccine Initiative Aids Vaccine Literacy Toolkit. Accessed 15/11/2010, International AIDS Vaccine Initiative., http://www.iavi.org/Lists/IAVIPublications/attachments/3c23d8e2-9f8b-4d67-a9a5-baaaed491fa9/IAVI_VAXLIT_Core_Content_2005_ENG.pdf
15. Tarimo EAM, Thorson A, Kohi T, Bakari M, Sandstrom E, Kulane A. Gender and sexual behavior among Phase I/II HIV Vaccine trial volunteers: a qualitative study among police officers in Dar es Salaam, Tanzania. XVII International AIDS Conference Volume 2 2008, Mexico City: International AIDS Society.
16. Kitzinger J, Barbour RS. Introduction: the challenge and promise of focus groups. Developing Focus Group Research: Politics, Theory and Practice 2001, London: SAGE Publications, Barbour RS, Kitzinger J.
17. Myers G, Macnaghten P. Can focus groups be analysed as talk?. Developing Focus Group Research: Politics, Theory and Practice 2001, London: SAGE Publications, Barbour RS, Kitzinger J.
18. Thorne S, Kirkham SR, MacDonald-Emes J. Interpretive description: a noncategorical qualitative alternative for developing nursing knowledge. Res Nurs Health 1997, 20(2):169-177. 10.1002/(SICI)1098-240X(199704)20:2<169::AID-NUR9>3.0.CO;2-I, 9100747.
19. Patton MQ. Qualitative Research and Evaluation Methods 2002, Thousands Oaks: Sage Publications, 3.
20. Thorne S. The Analytic Challenges in Interpretive Description. International Journal Of Qualitative Methods 2004, 3(1):1-11.
21. Lampinen TM, Chan K, Remis RS, Merid MF, Rusch M, Vincelette J, Logue K, Popovic V, Alary M, Schechter MT, Hogg RS. Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine. CMAJ 2005, 172(4):479-483. 10.1503/cmaj.1031785, 548409, 15710939.
22. Bartholow BN, Buchbinder S, Celum C, Goli V, Koblin B, Para M, Marmor M, Novak RM, Mayer K, Creticos C, Orozco-Cronin P, Popovic V, Mastro TD. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005, 39(1):90-101. 10.1097/01.qai.0000143600.41363.78, 15851919.
23. Guest G, McLellan-Lemal E, Matia DM, Pickard R, Fuchs J, McKirnan D, Neidig JL. HIV vaccine efficacy trial participation: men who have sex with men's experiences of risk reduction counselling and perceptions of risk behaviour change. AIDS Care 2005, 17(1):46-57. 10.1080/09540120412331305124, 15832833.
24. van Griensvan F, Keawkungwal J, Tappero JW, Sangkum U, Pitisuttithum P, Vanichseni S, Suntharasamai P, Orelind K, Gee C, Choopanya K. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS 2004, 18(2):295-301. 10.1097/00002030-200401230-00020, 15075548.
25. Tanzania Commission for AIDS (TACAIDS) Tanzania HIV/AIDS and Malaria Indicator Survey 2007-2008. 2008, Dar es Salaam: TACAIDS, Tanzania Commission for AIDS (TACAIDS).
26. UNAIDS Good Participatory Practice Guidelines for biomedical HIV prevention trials. Accessed 10/12/2010, UNAIDS., http://data.unaids.org/pub/Manual/2010/guidelines_biomedical_hiv_prevention_2010_en.pdf
27. Allen M, Lau CY. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention. Soc Sci Med 2008, 66(4):945-951. 10.1016/j.socscimed.2007.10.019, 18162272.
28. Holloway J, Todres L. The status of method: flexibility, consistency and coherence. Qualitative Research in Health Care 2005, London: Open University Press, Immy H.
29. Aboud S, Bakari M, Francis J, Buma D, Moshiro C, Aris E, Lyamuya E, Janabi M, Godoy-Ramirez K, Earl P, Robb M, Marovich M, Michael N, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandstrom E. Broad and strong immune responses in a trial of a heterologous DNA prime MVA boost HIV vaccine among healthy Tanzanian volunteers. AIDS VACCINE 2010: Atlanta - Georgia 2010, 68.
30. Farquhar C. Are focus groups suitable for 'sensitive' topics?. Developing Focus Group Research: Politics, Theory and Practice 2001, London: SAGE Publications, Barbour RS, Kitzinger J.
31. Holloway I, . (Ed.) A-Z of Qualitative Research in Healthcare 2008, London: Blackwell Publishing, (Ed.).
32. Hunt MR. Strengths and challenges in the use of interpretive description: reflections arising from a study of the moral experience of health professionals in humanitarian work. Qual Health Res 2009, 19:1284-1292. 10.1177/1049732309344612, 19690208.